Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2018; 24(2): 195-210
Published online Jan 14, 2018. doi: 10.3748/wjg.v24.i2.195
INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
Jonathan D Roth, Michael Feigh, Sanne S Veidal, Louise KD Fensholdt, Kristoffer T Rigbolt, Henrik H Hansen, Li C Chen, Mathieu Petitjean, Weslyn Friley, Niels Vrang, Jacob Jelsing, Mark Young
Jonathan D Roth, Mark Young, Intercept Pharmaceuticals, Intercept Pharmaceuticals, San Diego, CA 92121, United States
Michael Feigh, Sanne S Veidal, Louise KD Fensholdt, Kristoffer T Rigbolt, Henrik H Hansen, Niels Vrang, Jacob Jelsing, Gubra, Hoersholm DK-2970, Denmark
Li C Chen, Mathieu Petitjean, PharmaNest, Genesis Imaging Services, Princeton, NJ 08540, United States
Weslyn Friley, Qualyst Transporter Solutions, Durham, NC 27713, United States
Author contributions: Studies were designed by Roth JD, Feigh M, Petitjean M and Young M; Fensholdt LKD Fensholdt, Veidal SS, Rigbolt KT, Chen LC and Friley W performed the majority of experiments; Hansen HH and Roth JD wrote the paper with significant contributions to data analyses and editing by all co-authors.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals (licence no. 2013-15-2934-00784, The Animal Experiments Inspectorate, Denmark).
Conflict-of-interest statement: Jonathan Roth and Mark Young are employed by and hold equity in Intercept Pharmaceuticals, Inc. All other authors have nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Henrik H Hansen, PhD, Principal Scientist, Pharmacology, Gubra, Kongevej 11B, Hoersholm DK-2970, Denmark.
hbh@gubra.dk
Telephone: +45-23-1522651
Received: October 23, 2017
Peer-review started: October 25, 2017
First decision: November 14, 2017
Revised: November 24, 2017
Accepted: December 5, 2017
Article in press: December 5, 2017
Published online: January 14, 2018
Processing time: 82 Days and 23.7 Hours
